Tuesday, 17 November 2026
NEXA NEWSHD
Health

FDA Approves Roche’s Wilserdly Pill for Drug-Resistant Advanced Breast Cancer

The United States Food and Drug Administration has approved Roche’s once-daily pill Wilserdly for a form of advanced breast cancer that has stopped responding to hormone therapy, giving patients whose tumours carry a specific genetic mutation a new, fully oral treatment option. The decision, announced on Monday 16 November, rests on a late-stage trial in which the drug cut the risk of the cancer progressing or killing the patient by 62 per cent compared with the standard hormone treatment, according to Reuters.

Wilserdly, known generically as giredestrant, is approved in combination with everolimus, an existing targeted drug, for adults with oestrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer whose tumours carry an ESR1 mutation and whose disease has come back during or after hormone-based treatment, or has progressed on at least one hormone-based regimen in the advanced setting. The approval also covers a blood test, FoundationOne Liquid CDx, that identifies the patients whose tumours carry the mutation and who therefore qualify for the drug.

For the women affected, the approval matters because of what it replaces as much as what it adds. Until now, the most widely used drug in this class, fulvestrant, had to be given as two large injections into the buttocks every month in a clinic. Wilserdly is a 30-milligram tablet taken once a day at home, alongside everolimus, which is also a tablet. Roche’s chief medical officer, Dr Levi Garraway, said in the company’s announcement that the combination “allows advanced breast cancer patients to take their treatment from home”.

Roche, the Swiss drugmaker, has called Wilserdly its biggest potential blockbuster, and analysts at Citi expect the medicine to reach peak annual sales of 14.5 billion dollars, Bloomberg News reported. The company said it would launch the drug in the United States almost immediately, with a patient-support programme designed to help women start treatment quickly. A Roche spokesperson told Reuters the treatment will be priced at 22,500 dollars a month before discounts or rebates.

What the FDA approved

The approval covers a precisely defined group of patients, and the precision is the point. Breast cancer is not one disease. About 70 per cent of cases are hormone receptor-positive and HER2-negative, meaning the tumour cells carry receptors for oestrogen and do not overproduce the HER2 protein. Those cancers are usually treated first with hormone therapy, which starves the tumour of oestrogen or blocks the hormone’s effect, often combined with a class of drugs called CDK4/6 inhibitors. For many women that approach works for years. For a large minority, it eventually stops working, and the reason is very often a mutation in a gene called ESR1.

ESR1 is the gene that carries the instructions for building the oestrogen receptor itself. When it mutates, the receptor can switch itself on even when no oestrogen is present, so hormone therapies that work by lowering oestrogen levels lose their grip. According to Roche, up to 40 per cent of patients with hormone receptor-positive metastatic breast cancer develop ESR1 mutations that drive resistance and disease progression. The mutations are, in Roche’s words, “considered the primary cause of hormone therapy resistance” in this setting.

Wilserdly is a next-generation oral selective oestrogen receptor degrader, or SERD. It is designed to bind to the oestrogen receptor, block oestrogen from attaching to it, and then trigger the breakdown of the receptor protein itself, stopping or slowing the growth of the cancer cells. Everolimus, its partner drug, blocks a different signalling route, the mTOR pathway, which tumours also use to escape hormone therapy. Roche said the two drugs attack two different signalling pathways at once, and that Wilserdly’s effect is “synergistically enhanced” when combined with an mTOR inhibitor.

The approval came four weeks ahead of the FDA’s target date, according to the trade publication Technology Org, and the agency reviewed the drug under Project Orbis, a programme that allows regulators in several countries to review cancer medicines together. Health Canada and Israel’s Ministry of Health took part in the review.

The trial behind the approval

The approval rests on the phase III evERA Breast Cancer study, a randomised, open-label, multicentre trial whose results were published in the New England Journal of Medicine. The trial enrolled 373 adults with oestrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer who had previously been treated with a CDK4/6 inhibitor and hormone therapy, and compared Wilserdly plus everolimus against a standard hormone therapy plus everolimus.

In the 207 patients whose tumours carried an ESR1 mutation, the Wilserdly combination cut the risk of disease progression or death by 62 per cent, a stratified hazard ratio of 0.38, with a 95 per cent confidence interval of 0.27 to 0.54 and a p-value of less than 0.0001, according to the Roche announcement. The median time before the cancer worsened or the patient died was 10 months with the Wilserdly combination, compared with 5.5 months with the standard combination, Reuters reported.

Dr Erica L. Mayer, director of breast cancer clinical research at the Dana-Farber Cancer Institute, said the trial showed the oral combination “directly targets the primary genomic drivers of resistance, offering patients prolonged disease control through a fully oral therapeutic option”. Patients with advanced breast cancer whose disease progresses on hormone therapies, she said, “often face difficult choices and deteriorating quality of life as options narrow”.

Two points about the numbers deserve care. First, the 62 per cent figure is a relative reduction in the risk of progression or death during the trial. It does not mean that 62 per cent of patients were cured, and it does not mean deaths were cut by the same proportion. Second, the trial measured progression-free survival, the time before the cancer grows again, rather than overall survival. It is too soon to determine whether the medicine helps patients live longer overall, the FDA said, according to Bloomberg, because the survival data were not yet mature when the agency reviewed the results. Overall survival is a key secondary endpoint of the trial, and that data will be watched closely when it arrives.

The drug also carries warnings. Its label warns about the risk of bradycardia, a dangerously slow heart rate, and about foetal toxicity for pregnant women, Bloomberg reported. Analysts at Citi said they did not expect the warning to impede uptake of the drug.

Why resistance happens: the ESR1 problem

To understand why this approval matters, it helps to understand what usually happens to a woman with hormone-sensitive breast cancer. The disease is the most common cancer in women worldwide. According to Roche, 2.3 million women are diagnosed with breast cancer every year and 670,000 die from it, making it the leading cause of cancer-related death among women and the second most common cancer type overall. More than 90 per cent of hormone receptor-positive, HER2-negative cases are diagnosed at an early stage, when surgery and follow-up hormone therapy can often cure the disease outright.

But the cancer returns in a significant minority of patients, and when it comes back it is usually metastatic, meaning it has spread beyond the breast. At that point the disease is generally treated rather than cured, and the aim becomes keeping it under control for as long as possible while preserving quality of life. Hormone therapy plus a CDK4/6 inhibitor has been the standard first treatment in this setting for a decade, and it works well for many women. The problem is what happens next.

Cancers evolve under pressure. As a tumour is exposed to hormone therapy month after month, the cells that survive are the ones that have found a way around the drug. The ESR1 mutation is the most common escape route, and it is, in a sense, the tumour learning the drug’s trick and turning it inside out. The receptor that hormone therapy was designed to starve begins to fire on its own, without any hormone at all. Once that happens, drugs that lower oestrogen levels have nothing left to lower, and the cancer grows again.

That is why a drug that destroys the receptor itself, rather than merely starving it of hormone, has been so eagerly pursued. The idea is old. Fulvestrant, the first drug in this class, was approved more than twenty years ago and is still used. But it is an injection, it is painful, and it has to be given in a clinic. The pharmaceutical industry has spent years trying to make an oral version that works as well or better. The first oral SERD, elacestrant, sold as Orserdu, was approved by the FDA in 2023. Eli Lilly’s imlunestrant, sold as Inluriyo, received US approval in 2025. Wilserdly is the third, and Roche argues it is the most potent of the three, with preclinical data showing stronger activity at one of the lowest doses among oral SERDs.

What it costs, and what it does not yet prove

At 22,500 dollars a month, Wilserdly sits squarely among the most expensive modern cancer treatments. The list price is before discounts or rebates, and Roche said it was preparing a patient-support programme, but the figure will revive the familiar argument about the price of cancer drugs in the United States. A woman who stays on the drug for the median time seen in the trial, about ten months, would face a list-price bill of roughly 225,000 dollars. Insurers, not patients, pay most of that in the American system, but the cost lands on premiums, on co-payments and on the public purse, and the question of who can actually get the drug is never settled by an FDA approval alone.

The approval is also narrow. It covers only patients whose tumours carry the ESR1 mutation, confirmed by an FDA-authorised test, and only after hormone therapy has failed. That is the right way to use a targeted drug, but it means the benefit reaches a defined subset of patients, not every woman with advanced breast cancer. The blood test that identifies them, FoundationOne Liquid CDx, analyses circulating tumour DNA from a blood sample, which means a woman can be tested without a new tissue biopsy, but it also means the testing infrastructure has to be in place before the drug can be prescribed.

There is a larger question hanging over the approval, and the FDA itself has flagged it. The trial proved that Wilserdly delays the cancer’s progression. It has not yet proved that it extends life. That is not unusual: progression-free survival is an accepted basis for approval in advanced cancer, and regulators and doctors accept it because delaying progression usually means delaying symptoms, delaying the next round of chemotherapy and buying time. But the history of cancer drugs contains examples where a drug delayed progression without extending life, and where the side effects of the extra months were not trivial. The overall survival data from evERA will be the real test of whether this drug changes the course of the disease or merely changes its timetable.

Analysis: Why It Matters

A pill that attacks the mutation, not just the hormone

The most important thing about Wilserdly is not that it is new. It is that it is aimed at the right enemy. For years, the treatment of hormone-sensitive breast cancer has been a story of better and better ways to deprive a tumour of oestrogen, while the tumour quietly rewrote the receptor that oestrogen acts on. The ESR1 mutation is the single most common reason hormone therapy fails, and until recently there was no widely available oral drug designed specifically to destroy the mutated receptor. Wilserdly is built for exactly that job. It does not lower oestrogen and hope the receptor stays quiet. It binds to the receptor and marks it for destruction. That is a different kind of medicine, and it is why oncologists have followed this drug’s development so closely even though the class already had two approved members. The question was never whether an oral SERD could be made. It was whether one could be made potent enough, at a low enough dose, to matter in patients whose cancers had already outwitted two or three previous treatments. The evERA numbers suggest that this one can.

Four and a half months is the number that matters, and the number that does not

Ten months versus five and a half. That is the median gain in progression-free survival, and it is worth pausing on what four and a half months actually means to a person with metastatic breast cancer. It is four and a half months without the scan that shows the cancer growing again. Four and a half months without switching to chemotherapy, with its hair loss and nausea and fatigue. Four and a half months of a daily pill taken at home instead of a clinic visit. That is a real benefit, and it is the benefit the FDA approved the drug for. But four and a half months is also a median, which means half of patients got less, and it is a measure of delay, not of cure. Nobody in the evERA trial was cured. The honest way to describe Wilserdly is that it buys time, and time, for a person living with an incurable disease, is not a small thing. But it is not the same as changing the outcome, and the distinction matters, because the price of the drug and the size of the claims made for it will both be judged, eventually, against whether patients actually live longer.

The 22,500-dollar question: who actually gets this drug

Every cancer drug approval in the United States now comes with a second, unspoken approval process, conducted by insurers, and Wilserdly’s will be a hard one. At 22,500 dollars a month, the drug costs about 270,000 dollars a year at list price. Roche will argue, with reason, that the drug is for a narrowly defined group of patients, that the trial result is strong, and that an oral drug taken at home saves the health system the cost of clinic visits and injections. Insurers will argue, also with reason, that the overall survival benefit is unproven and that the price is set at whatever the market will bear. The patients caught between those two arguments will be the ones who have to navigate prior authorisation forms, co-payment assistance programmes and the question of whether their tumour test was done with the right assay. The history of expensive targeted cancer drugs suggests that most American patients with good insurance will get Wilserdly without much difficulty, and that the drug will be largely unavailable, for years, to women in Pakistan, in much of Africa and in most of the rest of the developing world, where breast cancer kills a disproportionate share of its victims precisely because modern treatments arrive late or not at all. The FDA’s decision is a scientific event. Access is a political one, and it has not been decided.

Roche’s 14.5-billion-dollar bet, and why 30 November matters more

For Roche, Monday’s approval is the beginning of the story, not the end. The company has spent more than three decades building its breast cancer business, from Herceptin, the drug that transformed HER2-positive breast cancer from a death sentence into a treatable disease, to Kadcyla, its successor. But Roche’s oncology business has been under pressure as older drugs lose patent protection and rivals, notably AstraZeneca, push ahead with competing medicines. Citi’s estimate of 14.5 billion dollars in peak annual sales would make Wilserdly one of the biggest-selling cancer drugs in history, and that figure assumes something Monday’s approval does not deliver: use in early-stage disease, where the patient numbers are vastly larger. That is why the date to watch is 30 November, when the FDA is due to decide on Wilserdly as an adjuvant treatment, given after surgery to stop early-stage cancer coming back. The application is based on the lidERA trial, and if it is approved, Wilserdly would be the first new adjuvant endocrine therapy in more than twenty years and the first SERD approved for both early and advanced oestrogen receptor-positive breast cancer. That decision, more than Monday’s, will determine whether Wilserdly is a valuable drug for a niche of patients or a drug that reshapes the treatment of the most common form of breast cancer.

The oral SERD race is now a real market, and patients are the winners

There is a quieter story underneath the headlines about price and sales forecasts, and it is a good one. Three years ago, there was one oral SERD on the market. Now there are three, with a fourth and fifth in late-stage development, and the competition is already changing the field. AstraZeneca is pushing its own candidate. Eli Lilly’s drug is already approved. The existence of rivals forces each company to run bigger trials, to test its drug in earlier stages of disease, to prove not just that it works but that it works better than the alternatives, and to price with at least one eye on the competition. That is how a class of drugs matures, and it is how patients end up with choices rather than take-it-or-leave-it options. The risk is that the competition is fought mostly in the wealthy world, in trials run in rich countries and priced for rich health systems, while the women who die of breast cancer in the largest numbers, in countries without routine screening and without access to targeted therapy at all, see none of it. The oral SERD race is a genuine scientific achievement. Whether it becomes a global one depends on decisions that have not yet been made, about price, about licensing, and about whether a drug that costs 22,500 dollars a month can ever reach the places where it is needed most.

What to Watch Next

  1. 30 November: The FDA’s decision on Wilserdly as adjuvant therapy for stage I to III oestrogen receptor-positive, HER2-negative breast cancer, based on the lidERA trial. Approval would make it the first new adjuvant endocrine therapy in more than twenty years.
  2. The United States launch: Roche said Wilserdly will be available in the coming weeks. Watch how quickly insurers cover it, how the patient-support programme works in practice, and whether the 22,500-dollar monthly price draws political attention.
  3. Overall survival data from evERA: The trial’s key secondary endpoint. When the survival data mature, they will show whether delaying progression also means extending life, which is the result that would settle the drug’s real value.
  4. Regulatory filings outside the United States: Roche said additional filings are under way in markets outside the US. The drug was reviewed under Project Orbis with Health Canada and Israel’s Ministry of Health, which may speed approvals there.
  5. Rival oral SERDs: AstraZeneca’s competing medicine and further data from Eli Lilly’s Inluriyo will show whether Wilserdly’s trial results stand up against the rest of the class, and whether head-to-head comparisons are ever run.
  6. Further trial readouts: Roche’s programme includes six phase III trials. Results are still pending from pionERA, which pairs Wilserdly with a CDK4/6 inhibitor, and heredERA, which tests it in HER2-positive disease.
  7. Access beyond wealthy health systems: Whether Roche licenses the drug, agrees tiered pricing or supports access programmes for lower-income countries will determine whether the benefit of this approval reaches beyond the United States and Europe.

Sources

About the Author — Abdul Mannan

Leave a Reply

Your email address will not be published. Required fields are marked *